The injection pathway for weight management

Section 1 of 5 · 1 min read

NICE TA875 recommends injectable semaglutide in a specialist weight-management service, with a maximum two-year treatment period under that pathway. Its established maintenance dose is 2.4 mg weekly. This is a specific NHS recommendation; it does not mean every licensed injection strength or every semaglutide use has identical funding rules.

The obesity guidance describes a weight-related comorbidity with BMI at least 35, or BMI 30–34.9 when specialist-referral criteria are met, with lower thresholds for specified ethnic backgrounds. The service assesses the whole clinical picture. Meeting a number on a webpage is not confirmation that treatment will be offered.

A separate cardiovascular pathway

Section 2 of 5 · 1 min read

NICE TA1152, published in May 2026, concerns semaglutide for adults with established cardiovascular disease and overweight or obesity to reduce further major cardiovascular events. It is a separate clinical indication and recommendation. Ask the treating clinician whether it is relevant; it is not a way to bypass weight-management referral criteria.

Where the tablet fits

Section 3 of 5 · 1 min read

The MHRA authorised oral Wegovy in June 2026. Its announcement said NHS availability had not then been established. The injection’s funded pathway cannot simply be applied to the tablet. Our source review found no verified final newer tablet funding decision to promise here.

For costs outside an NHS pathway, use iGovy for the injection and Ogovy for the pill. These are Med Easy’s formulation-specific price references. Do not compare milligrams across the formulations or change product without your prescriber.

Finding the service that covers your area

Section 4 of 5 · 1 min read

A local NHS weight-management team may deliver care directly or commission another provider. Our NHS service directory gives verified examples and their catchments. In Sussex, the published Tier 3 pathway names Morelife and links medicine provision to the local Wegovy policy.

Prepare three questions for the referring team: which programme is appropriate, how the referral is sent, and what acceptance into the programme means. A programme may offer several forms of support; acceptance does not determine the medicine decision.

Plan beyond the first appointment

Section 5 of 5 · 1 min read

Ask what the service will review over time, how it communicates with your GP and what happens when the funded treatment period or programme ends. A useful plan includes the transition, not only the first prescription.

  • Who explains the decision after assessment?
  • What support is provided between reviews?
  • Who manages any change in treatment?
  • How will you know when the next appointment is due?
  • What continuing care will be available afterwards?

Turn information into a plan

Five questions to take with you

Tick a question when you have an answer. These reminders stay on this page and are not saved.

0 of 5 questions answered

Build an appointment plan →

Your questions, answered

Does the injection’s NHS recommendation include Wegovy tablets?

Do not assume that it does. Formulations have separate prescribing and funding questions, even when the brand name is shared. Ask the NHS service about the current tablet position specifically. For a private comparison, keep tablet listings and injection listings separate and follow the formulation on your prescription.

Answer link

Is the two-year limit a rule for every use of Wegovy?

The maximum two-year period described in this guide belongs to NICE’s specialist weight-management recommendation. It should not be applied automatically to a different indication or pathway. Ask the treating service which recommendation governs your care and how its review and duration rules would be explained before treatment begins.

Answer link

Will joining a specialist programme guarantee Wegovy?

A referral is for assessment and support under that service’s criteria. Acceptance into a programme is not a promise of a chosen medicine. Ask what decisions the first assessment makes, what other support the service provides and who will explain the options available for your circumstances after reviewing your history.

Answer link

Sources & further reading

Source material checked 20 October 2026. Follow the original publication to check current arrangements. The source labels describe the publisher; they are not a quality rating.

Explore the full source library → · How we use evidence →